Korro Bio Management
Management criteria checks 1/4
Korro Bio's CEO is Ram Aiyar, appointed in Nov 2020, has a tenure of 5.08 years. total yearly compensation is $939.08K, comprised of 65% salary and 35% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth $36.95K. The average tenure of the management team and the board of directors is 1.5 years and 1.7 years respectively.
Key information
Ram Aiyar
Chief executive officer
US$939.1k
Total compensation
| CEO salary percentage | 64.96% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 1.5yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?
Oct 23
We're Keeping An Eye On Korro Bio's (NASDAQ:KRRO) Cash Burn Rate
Jul 05Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?
Mar 19We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully
Nov 28We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully
Aug 15We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth
Mar 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$88m |
| Jun 30 2025 | n/a | n/a | -US$91m |
| Mar 31 2025 | n/a | n/a | -US$87m |
| Dec 31 2024 | US$939k | US$610k | -US$84m |
| Sep 30 2024 | n/a | n/a | -US$88m |
| Jun 30 2024 | n/a | n/a | -US$85m |
| Mar 31 2024 | n/a | n/a | -US$81m |
| Dec 31 2023 | US$3m | US$498k | -US$81m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$69m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$1m | US$473k | -US$58m |
Compensation vs Market: Ram's total compensation ($USD939.08K) is above average for companies of similar size in the US market ($USD577.34K).
Compensation vs Earnings: Ram's compensation has been consistent with company performance over the past year.
CEO
Ram Aiyar (47 yo)
Dr. Ram Aiyar, Ph.D. MBA, has been the Interim Chief Financial Officer and Principal Financial Officer at Korro Bio, Inc. since October 17, 2025. He serves as Director of Triveni Bio Inc. Dr. Aiyar has bee...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 5.1yrs | US$939.08k | 0.049% $ 36.9k | |
| Senior VP | 1.3yrs | US$1.82m | 0% $ 0 | |
| Advisor | 1.6yrs | US$2.90m | 0% $ 0 | |
| Co-Founder & Advisor | no data | no data | no data | |
| Co-Founder & Advisor | no data | no data | no data | |
| Chief Operating Officer | 2.3yrs | no data | no data | |
| Senior VP of Finance & Principal Accounting Officer | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Chief People Officer | 3.1yrs | no data | no data | |
| SVP of Chemistry | less than a year | no data | no data |
Experienced Management: KRRO's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 2.1yrs | US$939.08k | 0.049% $ 36.9k | |
| Co-Founder & Independent Director | 2.1yrs | US$201.48k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$209.98k | 0% $ 0 | |
| Co-Founder & Independent Chairman of the Board | 2.1yrs | US$237.48k | 0.37% $ 281.3k | |
| Independent Director | 2.1yrs | US$193.98k | 0% $ 0 | |
| Member of Clinical Advisory Board | 1.1yrs | no data | no data | |
| Independent Director | 1.3yrs | US$315.57k | no data | |
| Member of Clinical Advisory Board | 1.1yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.1yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.1yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.1yrs | no data | no data | |
| Independent Director | 2.1yrs | US$202.98k | 0% $ 0 |
Experienced Board: KRRO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 06:35 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Korro Bio, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Tu Cam Nguyen | CGS International |